Skip to content

Efficacy of mesalazine in the treatment of obesity-diarrhea syndrome

Efficacy of mesalazine in the treatment of obesity-diarrhea syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086899
Enrollment
Unknown
Registered
2024-07-15
Start date
2024-07-15
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity-diarrhea syndrome

Interventions

experimental group:mesalazine
control group:placebo

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Age range from 18 to 65 years old; 2) Long term chronic diarrhea: meets the diagnostic criteria for chronic diarrhea; 3) Obesity: BMI greater than 28kg/m2; 4) Routine examinations of the patient, such as blood, urine, stool, biochemistry, abdominal CT, gastrointestinal endoscopy, etc., did not show any organic lesions; (5) Sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Suffering from diseases such as intestinal infections, inflammatory bowel disease, irritable bowel syndrome, and malabsorption syndrome that can clearly cause diarrhea; (2) Patients who have undergone surgical procedures such as cholecystectomy and gastrointestinal resection; (3) Suffering from serious cardiovascular diseases, liver and kidney dysfunction, and other diseases, with contraindications for anesthesia; (4) Pregnant or breastfeeding patients.

Design outcomes

Primary

MeasureTime frame
Fecal frequency and Bristol fecal trait typing;

Secondary

MeasureTime frame
Related indicators such as blood and tissue inflammatory factors;

Countries

China

Contacts

Public ContactEnqiang Linghu

Chinese PLA General Hospital

wxymedicine@sina.com+86 186 1050 3660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026